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Background: Low bone mass and high bone turnover have been reported in HIV-infected individuals, both as a
consequence of HIV infection itself, as well as from treatment with highly active antiretroviral therapy (HAART). The
purpose of this study is to evaluate the impact of HAART on bone mineral density and bone turnover in HIV-1
infected Chinese patients.
Methods: Forty HIV-1 infected patients were enrolled in this study; all patients were followed through 48 weeks,
and 17 patients completed 96 weeks. Bone mineral density (BMD), procollagen type 1 N-terminal propeptide
(P1NP), collagen type 1 cross-linked C-telopeptide (β-CTX), parathyroid hormone (PTH), and 25-OH vitamin D levels
were measured at baseline, 48 and 96 weeks. Baseline measurements were compared with an age-, gender-, and
BMI-matched healthy control population.
Results: At baseline, raw BMD in the lumbar spine of HIV-1 infected patients was significantly lower than that
of healthy controls (1.138 ± 0.112 g/cm2 vs. 1.195 ± 0.139 g/cm2, p = 0.047). During the first 48 weeks after
initiating HAART, BMD of lumbar spine, femoral neck, and total hip decreased significantly in HIV-1 infected
patients, with annual percent decline ranging from 1.78-3.28%. However, from week 48 to 96, BMD remained
stable. Baseline levels of β-CTX (0.31 ± 0.16 ng/mL vs. 0.42 ± 0.19 ng/mL, p = 0.008) and P1NP (32.96 ± 14.00 ng/mL
vs. 55.82 ± 26.87 ng/mL, p = 0.05) were lower in HIV-infected patients compared with controls, respectively. Both
β-CTX and P1NP levels increased after onset of HAART until week 48, and remained elevated during the next
48 weeks. 25-OH vitamin D in HIV-infected patients was lower at baseline compared to healthy controls, but this
difference was not statistically significant. PTH, however, was higher in HIV patients at baseline, and showed a
significant increase throughout the study.
Conclusions: Chinese adults with HIV-1 infection have low bone turnover prior to HAART as well as lower raw BMD
of the lumbar spine compared with healthy controls, with further bone loss occurring following the initiation of
HAART. The long-term clinical implications of these findings remain unclear at this time.
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Low bone mass and high bone turnover have been reported
in HIV-infected individuals, both as a consequence of HIV
infection itself [1-4], as well as from treatment with highly
active antiretroviral therapy (HAART) [5-7]. The rapid
decline in bone mineral density (BMD) and rise in bone
turnover markers (BTM) that has been observed in patients
treated with HAART is especially pronounced during the
first six months after initiation of HAART, and is followed
by eventual stabilization of these parameters after one
to two years [8-10]. Moreover, Vitamin D deficiency
and secondary hyperparathyroidism may also be seen
concurrently [11-15].
Limited reports have described the impact of HIV and
HAART on BMD in HIV-infected Chinese. We previously
observed lower BMD among a cross-sectional cohort of
62 HIV-infected patients compared to 20 non-infected
controls [4]. No studies have been published regarding
bone turnover among this population. It is possible that
the bone metabolism of Chinese HIV-infected patients
treated with HAART differs from that of other races.
Yao et al. found that Chinese patients receiving HAART
manifest a distinct pattern of lipodystrophy compared
with Western populations [16]. As well, pharmacokinetic
differences among Chinese HIV-1infected patients
receiving HAART have been documented. Data from
Wang et al. indicate that the ideal Nevirapine trough
concentrations to achieve efficacy appears to be higher
among Chinese HIV-1 infected individuals than the
cutoff of 3.0 ug/ml suggested by previous cohort studies
conducted in Caucasian patients [17,18].
The present study measures baseline BMD and bone
turnover in a cohort of 40 HIV-infected individuals
compared with 40 sero-negative healthy controls, and also
examines the change in BMD, BTMs, parathyroid hormone
(PTH) and 25-OH vitamin D in the HIV-1 infected patients
during the 96 weeks after initiation of HAART.
Methods
Subjects
From April 2007 to March 2011, all adult patients (≥18 years
of age) infected with HIV-1 and naive to ART presenting
for care in the infectious disease clinic of Peking Union
Medical College Hospital (PUMCH) were invited to partici-
pate in this study. Patients were excluded from the study if
they had any of the following conditions: (1) significant
renal, hepatic, thyroid or parathyroid dysfunction; (2) malig-
nancies; (3) recent opportunistic infection; (4) a history of
wasting syndrome; (5) intravenous injection drug use; (6)
use of systemic glucocorticoids; (7) use of anti-osteoporotic
agents; and (8) pregnant or nursing women.
A total of 201 patients were screened and of those,
forty patients were both willing and met eligibility
criteria for the study (35 males and 5 females). Healthycontrols matched for age, gender, and BMI were recruited
voluntarily from the general medicine clinic at PUMCH.
All controls were tested and confirmed to be negative for
HIV-1 at the time of enrollment. This study was approved
by ethics committee of PUMCH, and written informed
consent was obtained from each subject at the time of
enrollment into the study.
After collection of baseline measurements, patients with
HIV-1 infection were initiated on antiretroviral therapy
with two nucleoside reverse transcriptase inhibitors
(NRTIs) plus one non-nucleoside reverse transcriptase
inhibitor (NNRTI), according to standard antiretroviral
(ARV) regimens used in China. These regimens included
Stavudine (D4T, 40 mg, twice daily) or Zidovudine
(AZT, 300 mg, twice daily), paired with Lamivudine
(3TC, 300 mg, once daily) and Nevirapine (NVP, 200 mg,
twice daily for 14 days, followed by 200 mg once daily).
All forty HIV-1 infected patients completed 48 weeks
of follow-up, and 17 patients completed 96 weeks of
follow-up.
Procedures and measurements
Baseline and follow-up measurements: Upon entry into the
study, weight and height was recorded for all participants.
For all the patients at baseline and controls, bone mineral
density was determined by dual X-ray absorptiometry
(DEXA), serologic samples were taken and stored at −80°C
until analysis for bone turnover markers, 25-OH vitamin D
and PTH. In HIV-1 infected subjects, plasma viral load
and peripheral lymphocyte subpopulation analysis were
also evaluated. HIV-1 infected subjects were then followed
prospectively and re-evaluated at weeks 48 and 96. At each
of these time points, bone mineral density and serologic
analysis was repeated.
Bone mineral density measurements: Bone mineral
density of the total hip, femoral neck, and lumbar
spine (the first to fourth lumbar vertebrae) was mea-
sured using the Lunar Prodigy Advance PA + 300388
(GE Healthcare, USA) (inter-assay CV for lumbar spine,
femoral neck and total hip is 0.76%, 1.15% and 0.62%
respectively). All measurements were performed in dorsal
decubitus position using the same DEXA scanner,
and results were interpreted using GE lunar software
(enCORE version 10.50.086) by a single investigator.
Laboratory measurements: Electro-chemiluminescence
immunoassay (Roche, modular analytics e 170, cobas e 601)
was used to evaluate bone formation marker total pro-
collagen type 1 N-terminal propeptide (P1NP; inter-assay
and intra-assay coefficients of variation [CV] 3.8% and
2.9%, respectively) and the bone resorption marker serum
collagen type 1 cross-linked C-telopeptide (β-CTX;
inter-assay CV 7.6%, intra-assay CV 5.5%), PTH (inter-
assay CV 3.4%, intra-assay CV 2.0%) and 25-OH vitamin D
(inter-assay CV 13.1%, intra-assay CV 6.8%) .
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via ELISA (Wantai, HIV Ag-Ab 0496). For HIV-infected
patients enrolled in the study, routine laboratory tests
for peripheral lymphocyte subpopulation analysis and
HIV RNA were performed at baseline and during
follow-up. To determine the counts and proportion of
CD4+T cells and CD8+T cells, peripheral lymphocyte
subpopulation analysis was performed using whole blood
samples and BD FACS canto (BD Bioscience, USA).
HIV-1 plasma viral load was detected by Roche COBAS
TaqMan (Roche, CA, USA2E2).Statistical analysis
Median and interquartile range (IQR) were calculated for
CD4+T and CD8 +T cell counts as well as viral loads and
mean ± standard deviation calculated for other baseline
variables. Baseline comparisons of categorical variables
between the two study groups were performed using the
Student’s t-test for independent samples. Repeated
measures analysis was used to assess for changes in BMD,
β-CTX, P1NP, PTH and 25-OH vitamin D over time
among patients with HIV-1 infection. All statistical
analysis was performed using the software package SPSS
16.0 (SPSS Inc., Chicago, IL, USA). Statistical significance
was set at the level of 0.05 and all p-values were 2-tailed.Results
Baseline characteristics
Forty HIV-1 infected, ART-naive patients were enrolled in
the study, including 35 men (mean age 37.30 ± 10.11 years,
range 20–55 years, mean BMI 22 ± 3.31 kg/m2) and five
women (mean age 39.2 ± 9.26 years, range 31–54 years,
BMI 24.56 ± 6.65 kg/m2). The study participants reflected
the overall clinic population in terms of ethnicity
(almost exclusively Han Chinese) and age distribution.
However a greater proportion of the study population
was male compared to the overall clinic population
(87.5% v. 75.1%, p = 0.042). Forty age-, gender- and
BMI-matched control subjects were enrolled and their
baseline characteristics compared with the HIV-infected
patients is shown in Table 1. The major route of transmis-
sion among HIV-1 infected patients was sexual intercourse
(70%), with the remaining HIV-1 infections attributable to
paid blood donation. At baseline, the median CD4+ T cell
count in the HIV group was 137 (IQR 63–204) cells/μL,
and the median plasma viral load was 4.42(IQR 3.59-4.86)
log copies/mL. Therefore, the majority of the HIV-infected
patients met diagnostic criteria for AIDS.
In this study, all HIV-1 infected patients demonstrated
a robust response to ART initiation, with undetectable
HIV-1 RNA levels by week 48, and mean CD4+T cell
counts of 242 (IQR 151–327) cells/μL at week 48 and
256(206–463) cells/μL at week 96.Change in BMD before and after HAART
There were no cases of osteoporosis or osteopenia in
our study population at baseline or during the follow
up period. However at baseline, the mean raw BMD
in the lumbar spine of HIV-1 infected patients was
significantly lower than that of healthy controls
(1.138 ± 0.112 vs. 1.195 ± 0.139 g/cm2, p = 0.047), although
this difference was not reflected in the BMD Z-score.
There was no significant difference in mean raw BMD at
the femoral neck and total hip compared with the
controls, nor in the Z-scores (Table 1).
Raw BMD of the lumbar spine, femoral neck and total
hip decreased significantly in HIV-1 infected patients
from baseline to week 48 after initiating HAART
(lumbar spine 1.138 ± 0.112 vs. 1.112 ± 0.113, p = 0.022;
femoral neck 0.972 ± 0.136 vs. 0.940 ± 0.135, p = 0.000;
total hip 1.015 ± 0.147 vs. 0.996 ± 0.142, p = 0.002). A sig-
nificant decrease was also seen in the BMD Z-score at the
femoral neck (0.255 ± 1.018 vs. -0.0125 ± 0.942, p = 0.014),
but not at the lumbar spine or total hip. From week 48
to 96, BMD did not change significantly (Table 2).
Calculation of the annual percent change in BMD
showed a decline of 2.104 ± 5.572% at the lumbar spine,
3.28 ± 4.37% at the femoral neck, and 1.78 ± 3.47% at the
total hip from baseline to week 48. Percent change in
BMD at all sites remained essentially stable from week
48 to week 96.
Change in BTMs in HIV-1 infected patients treated with
HAART
At baseline, the mean level of the bone formation
marker P1NP was lower in HIV-1 infected patients than
in the controls (32.96 ± 14.00 vs. 55.82 ± 26.87 ng/mL,
respectively, p = 0.000). As well, the mean level of the
bone resorption marker β-CTX was lower in HIV-1
infected patients compared with the controls (0.31 ± 0.16
vs. 0.42 ± 0.19 ng/mL, respectively, p = 0.008).
From baseline to week 48, among HIV-1 infected
patients taking HAART, both P1NP and β-CTX dem-
onstrated a statistically significant increase compared
with the baseline (Figure 1a and 1b), with an average
percent increase of 54.44% for P1NP and 33.77% for
β-CTX. This was followed by a plateau, with P1NP
and β-CTX remaining stable from week 48 to week
96 (Figure 1a and 1b).
25-OH vitamin D and PTH levels in HIV-1 infected patients
treated with HAART
25-OH vitamin D levels among HIV-1 infected patients
in our study were low prior to HAART and remained
low during follow-up. Mean 25-OH vitamin D levels in
HIV-1 infected patients at baseline were lower than
healthy controls, but this difference was not statistically
significant (15.93 ± 6.49 ng/mL vs. 19.12 ± 9.00 ng/mL,
Table 2 Bone mineral density and laboratory results at baseline, 48 and 96 weeks
HIV-infected patients p-value#
Variables Baseline Week 48 Week 96
BMD (mean g/cm2)
Lumbar spine 1.138 ± 0.112 1.112 ± 0.113 1.120 ± 0.111 0.022
Femoral neck 0.972 ± 0.136 0.940 ± 0.135 0.942 ± 0.133 0.000
Total hip 1.015 ± 0.147 0.996 ± 0.142 0.996 ± 0.140 0.002
BMD (mean Z score)
Lumbar spine 0.511 ± 0.838 0.288 ± 0.902 0.550 ± 0.691 0.053
Femoral neck 0.255 ± 1.018 −0.0125 ± 0.942 0.177 ± 0.831 0.014
Total hip 0.244 ± 1.102 0.105 ± 1.033 0.412 ± 1.004 0.164
β-CTX (mean ng/mL) 0.31 ± 0.16 0.41 ± 0.13 0.36 ± 0.12 0.000
P1NP (mean ng/mL) 32.96 ± 14.00 50.91 ± 21.97 49.53 ± 17.32 0.000
PTH (mean pg/mL) 41.78 ± 16.11 51.81 ± 15.96 65.06 ±20.59 0.000
25-OH vitamin D (mean ng/mL) 15.93 ± 6.49 15.04 ± 7.14 13.77 ± 7.16 0.343
Illustrations for Table 2. BMD: bone mineral density; lumbar spine: the first to fourth lumbar vertebrae; P1NP: procollagen type 1 N-terminal propeptide; β-CTX:
Type I collagen cross-linked C-telopeptide; PTH: parathyroid hormone. #P-value indicates comparison between baseline and week48.
Table 1 Baseline characteristics
Variables Controls HIV (+) Patients at baseline p-value
(n = 40) (n = 40)
Female/Male 5/35 5/35
Age (mean years) 37.19 ± 10.34 37.30 ± 9.92 0.756
BMI (mean kg/m2) 23.43 ± 3.35 22.32 ± 3.85 0.225
Duration of HIV infection (mean years) NA 5.85 ± 3.07
Viral load* (log10 copies/mL) NA 4.42 (3.59-4.86)
CD4+T cell count* (cells/μl) NA 137 (63–204)
CD4+T cell percentage (%) NA 10.78 ± 6.84
CD8+T cell counts* (cells/μl) NA 773 (539–1027)
CD8+T cell percentage (%) NA 57.73 ± 9.77
BMD (mean g/cm2)
Lumbar spine 1.195 ± 0.139 1.138 ± 0.112 0.047
Femoral neck 1.035 ± 0.166 0.972 ± 0.136 0.069
Total hip 1.060 ± 0.126 1.015 ± 0.147 0.146
BMD (mean Z score)
Lumbar spine 0.654 ± 1.077 0.511 ± 0.838 0.498
Femoral neck 0.382 + 1.189 0.255 ± 1.018 0.591
Total hip 0.377 ± 1.157 0.244 ± 1.102 0.604
β-CTX (mean ng/mL) 0.42 ± 0.19 0.31 ± 0.16 0.008
P1NP (mean ng/mL) 55.82 ± 26.87 32.96 ± 14.00 0.000
PTH (mean pg/mL) 22.92 ± 10.17 41.78 ± 16.11 0.000
25-OH vitamin D (mean ng/mL) 19.12 ± 9.00 15.93 ± 6.49 0.073
Illustrations for Table 1. *Values are expressed as median (interquartile range); BMI = weight (kg)/(height [m])2; BMD bone mineral density; lumbar spine: the first to
fourth lumbar vertebrae; P1NP procollagen type 1 N-terminal propeptide; β-CTX Type I collagen cross-linked C-telopeptide; PTH parathyroid hormone.
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Figure 1 The change of bone turnover markers, 25-OH vitamin D and PTH of HIV-infected patients at baseline, 48 weeks and 96
weeks. a - The change of P1NP of HIV-infected patients and the controls; b - The change of β-CTX of HIV-infected patients and the controls;
c - The change of 25-OH vitamin D of HIV-infected patients and the controls; d -The change of PTH of HIV-infected patients and the controls.
(Dotted lines indicate the value in healthy controls, and solid lines indicate the value of HIV-1 infected patients. Abbreviations: P1NP, procollagen
type 1 N-terminal propeptide; β-CTX, Type I collagen cross-linked C-telopeptide; PTH, parathyroid hormone).
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the initiation of HAART, mean 25-OH vitamin D
levels in HIV-1 infected individuals were found to be
significantly lower than that of baseline healthy con-
trols (15.04 ± 7.14 ng/mL at week 48, p = 0.028 and
13.77 ± 7.16 ng/mL at week 96, p = 0.035) (Figure 1c).
Mean PTH levels were higher among HIV-1 infected
patients at baseline than controls (41.78 ± 16.11 pg/mL
vs. 22.92 ± 10.17 pg/mL, respectively, p = 0.000), and
continued to rise during the follow-up period, reaching
51.81 ± 15.96 pg/mL at week 48 and 65.06 ± 20.59 pg/mL
at week 96 (Figure 1d).
Discussion
This is the first study that we know of reporting data on
bone turnover in Chinese HIV-1 infected individuals.
Our study demonstrated that prior to HAART, HIV-1
infected patients had lower BTM levels at baseline com-
pared with non-infected controls. This finding differs
from previously published studies, which have generally
shown either no significant difference or higher BTM
levels in untreated HIV-infected individuals compared
with healthy controls [10,19,20].
One potential reason for this difference is that
HIV-infected patients enrolled in our study had se-
vere disease, with a median CD4+T cell count of 137(IQR 63–204) cells/μL at baseline. Therefore at the
time of diagnosis and HAART initiation, most patients in
our study were already clinically diagnosed with AIDS.
Studies by Ankrust et al. and Serrano et al. previously
demonstrated lower bone formation in AIDS patients
compared with non-AIDS HIV-infected patients and
non-HIV infected patients [20,21]. The latter study
demonstrated reduced bone formation and osteoclast
numbers by histomorphometry in 22 HIV-infected patients
and found histomorphometric parameters were more
altered in patients with more severe disease. In terms
of bone turnover, osteocalcin levels were lower in patients
with more severe disease, however the authors were
unable to detect a significant difference in bone resorption
markers [21].
Furthermore, many studies in the general population
have sought to characterize the role that race plays in
bone metabolism. Epidemiologic and structural analyses
have demonstrated differences in fracture rates, bone
density, and bone architecture between populations of
different races, including Chinese individuals compared
to other races [22-25]. However understanding of the
biology of these differences is still limited and studies
investigating differences in biochemical markers of bone
turnover have yielded mixed results [26,27]. In Chinese
women tested at Peking Union Medical College Hospital,
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(personal communication, Department of Endocrinology,
PUMCH). By comparison, Eastell et al. reported average
values of 38 ± 10.7 ng/mL in European white women
tested by the same method [28]. Finally, as mentioned
previously, the pharmacokinetics of therapeutic agents,
including HAART, differs in Chinese patients compared
with Western populations [17], therefore the magnitude
of drug-specific effects of antiretrovirals on bone may be
different. Further investigation into the specific impact of
HAART on bone metabolism in Chinese HIV-infected
patients is warranted.
With regards to the subsequent changes in bone turnover
markers after initiation of HAART, in our study, levels of
β-CTX and P1NP increased significantly during the
first 48 weeks and stabilized from week 48 to 96,
which is consistent with previously published studies
[19,29,30]. These findings follow an inverse pattern
compared with our BMD data, which showed a lower
baseline raw BMD at the lumbar spine in patients
with HIV-1 infection prior to HAART compared with
healthy controls, followed by a decline in raw BMD
in the lumbar spine, femoral neck, and total hip during
the first 48 weeks of HAART, and subsequent stabilization
between 48 to 96 weeks. The inverse correlation between
BTM and BMD has been documented previously and
studies have shown that in high turnover states such as
menopause, this association becomes particularly strong
[31,32]. Previous studies in HIV-infected patients have
also demonstrated this inverse relationship [19,33].
Our BMD findings support the results of other studies
from the literature demonstrating a decline in BMD
among HIV-infected patients after initiation of HAART
that is most pronounced within the first year [9,34,35].
Although our study primarily found statistically significant
differences in the raw BMD, and only found a statistically
significant decline in Z-score at the femoral neck, we
believe that this may be related to the relatively young age
of our study population and small sample size. Indeed, the
annual percent change from baseline during the first year
after initiation of HAART in our study is consistent with
the magnitude of change that has been observed among
HIV-infected patients initiating HAART in prior studies
[34,36,37]. Finally, patients in our study were treated
with zidovudine- and stavudine-based regimens. Although
these are known to be associated with bone loss
among HIV-patients, the most profound effects have
been seen with Tenofovir and protease inhibitors
[5,7,37-40]. In 2012 Tenofovir was made available in
China as first-line therapy for HIV infected patients,
therefore it will be increasingly important for future
studies evaluating the impact of HAART on bone disease
among Chinese HIV-infected patients to include those
treated with Tenofovir-based regimens.In our study, the mean level of 25-OH vitamin D in
all groups was consistent with vitamin D deficiency
(< 20 ng/mL). Levels of vitamin D in HIV-1 infected
patients at baseline were lower compared with healthy
controls, although this difference was not statistically
significant, perhaps due to the limited sample size.
There was a corresponding significant elevation in
PTH levels in HIV-infected patients naive to HAART
compared with healthy controls, which continued to
increase with continued treatment. Prior studies in
HIV-infected populations have also documented low
vitamin D levels, and we suspect that larger scale
studies will confirm lower vitamin D levels in Chinese
HIV-infected patients compared with the healthy
population [14,41].
This degree of vitamin D deficiency in Chinese
HIV-infected patients was previously unrecognized
and has extraskeletal implications as well. Haug et al.
previously demonstrated an association between low
vitamin D and low CD4+T cells counts in HIV infected
patients [42], and a recent study showed that deficiency of
vitamin D may impair recovery of CD4+T cells [43,44].
Thus vitamin D supplementation may not only be
beneficial to bone metabolism, but may also help to
improve immune reconstitution.
Our study has a few limitations. First, the sample size
was small, in particular in the 96 week follow-up group,
prohibiting subgroup analyses and making it difficult to
draw conclusions regarding long-term effects. However,
we were able to assess statistically significant differences
in BMD and BTMs between HIV-infected patients at base-
line and the control group. Furthermore, the plateaus in
BMD and BTM observed from week 48 to week 96 are
consistent with other published studies. Second, intraven-
ous drug users were excluded from this study; however, if
anything, we would expect this to lead to underestimation
of the true bone mineral density among HIV-infected
patients. Third, we did not include measurement of serum
calcium, albumin and phosphorus, important indicators of
bone metabolism that would have provided a more
complete laboratory assessment of underlying bone status
in our study population. Finally, data was not gathered
regarding specific HAART regimen, tobacco history, or
alcohol consumption factors, which may impact the under-
lying bone mineral density of individual subjects in our
study. More detailed studies are needed to clarify the under-
lying bone metabolism in Chinese HIV-infected patients as
well as the long-term impact of HAART in this population,
given the biological and environmental differences between
Chinese patients and Western populations.
Conclusions
Chinese adults with HIV-1 infection have low bone
turnover prior to HAART as well as lower BMD at the
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http://www.biomedcentral.com/1471-2474/14/224lumbar spine compared with healthy controls, with
further bone loss occurring following the initiation of
HAART. Vitamin D insufficiency and deficiency with
associated secondary hyperparathyroidism are highly
prevalent in this population. Further research is needed to
elucidate the implications of these findings for screening,
prevention and management of bone loss and vitamin D
deficiency in this population.
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